VERA

Vera Therapeutics' stock price decreased by 41.0% from $50.64 at the beginning of 2026 to $29.88 by October 9, 2026. A significant positive event was the FDA's accelerated approval of Trutakna (atacicept-vymj) for IgA kidney disease on July 7, 2026, which was highlighted in a virtual investor event. The company participated in several healthcare conferences, including the TD Cowen 46th Annual Health Care Conference in March 2026, the Cantor Global Healthcare Conference 2026 on September 10, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Vera Therapeutics also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) and experienced a 14.28% decrease in short interest, indicating improving investor sentiment.